Laparoscopic surgery in rectal cancer patients taking anti-thrombotic therapy. Issue 4 (31st July 2020)

• Record Type: Journal Article
• Authors: Nozawa, Hiroaki; Shinagawa, Takahide; Kawai, Kazushige; Hata, Keisuke; Tanaka, Toshiaki; Nishikawa, Takeshi; Sasaki, Kazuhito; Kaneko, Manabu; Murono, Koji; Emoto, Shigenobu; Sonoda, Hirofumi; Ishihara, Soichiro
• Is Part Of: Minimally invasive therapy & allied technologies. Volume 29:Issue 4(2020)
• Page Start: 202
• Page End: 209
• Publication Date: 2020-07-31
• Subjects: Anti-thrombotic therapy -- laparoscopic surgery -- outcome -- postoperative complications -- rectal cancer; Endoscopy -- Periodicals; Interventional radiology -- Periodicals; Endoscopic surgery -- Periodicals; 617.05
• DOI: 10.1080/13645706.2019.1619583
• Languages: English
• ISSNs: 1364-5706

Abstract

Abstract: Background: Several previous studies have shown that laparoscopic resection of rectal cancer is a feasible option. However, its safety and efficacy in patients receiving long-term anti-thrombotic therapy (AT) remain unclear. Material and methods: We retrospectively reviewed 364 patients who underwent elective resection for rectal cancer via a laparoscopic approach between 2007 and 2018 in our institute. Patients were classified according to the long-term use of AT. AT was interrupted perioperatively with or without heparin bridging therapy in all anti-thrombotic users. Clinicopathological factors and surgical outcomes were analyzed between patient groups. Results: Thirty-two patients (9%) receiving AT were older and had lower albumin and hemoglobin levels than those not receiving AT (the non-AT group), and were predominantly male. Estimated blood loss and operative time in the AT group (median: 50 mL and 294 min) did not differ from those in the non-AT group (median: 20 mL and 295 min). There were no intergroup differences in the frequencies of other postoperative complications and oncological outcomes. Conclusions: Our results at the very least can support that laparoscopic surgery for rectal cancer is a safe and feasible option for patients taking long-term AT discontinued perioperatively.